Комбинация ибрутиниба и венетоклакса в терапии хронического лимфолейкоза: обзор последних данных клинических исследований

ОБЗОРЫ , , , , ,

А.А. Петренко1,2, М.И. Кислова1, Е.А. Дмитриева1, Е.А. Никитин1,2, В.В. Птушкин1,2,3

1 ГБУЗ «Городская клиническая больница им. С.П. Боткина ДЗМ», 2-й Боткинский пр-д, д. 5, Москва, Российская Федерация, 125284

2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, ул. Баррикадная, д. 2/1, Москва, Российская Федерация, 125993

3 ФГАОУ ВО «РНИМУ им. Н.И. Пирогова» Минздрава России, ул. Островитянова, д. 1, Москва, Российская Федерация, 117997

Для переписки: Мария Игоревна Кислова, 2-й Боткинский пр-д, д. 5, Москва, Российская Федерация, 125284; e-mail: xkislovamariax@gmail.com

Для цитирования: Петренко А.А., Кислова М.И., Дмитриева Е.А. и др. Комбинация ибрутиниба и венетоклакса в терапии хронического лимфолейкоза: обзор последних данных клинических исследований. Клиническая онкогематология. 2023;16(1):37–45.

DOI: 10.21320/2500-2139-2023-16-1-37-45

РЕФЕРАТ

Появление ингибиторов тирозинкиназы Брутона (BTK) изменило лечение пациентов с хроническим лимфолейкозом (ХЛЛ). Ибрутиниб, первый в своем классе ингибитор BTK, продемонстрировал высокую эффективность в многочисленных клинических исследованиях. Однако использование ингибиторов BTK в качестве монотерапии требует непрерывного лечения. Резистентность к ингибиторам BTK и тяжелые побочные эффекты неизбежно возникают при монотерапии ибрутинибом, что часто приводит к неэффективности лечения. Комбинация ингибитора BCL-2 венетоклакса с ингибитором BTK может улучшить эффективность терапии за счет синергизма действия препаратов на разные субпопуляции клеток ХЛЛ. Комбинированная терапия может привести к более глубоким ответам, обеспечивая потенциально фиксированную продолжительность лечения. В настоящем обзоре, сосредоточив внимание на комбинации ибрутиниба и венетоклакса, мы обобщаем последние данные клинических исследований, а также отвечаем на вопрос, касающийся обоснованности комбинированной терапии с точки зрения ее эффективности и профиля безопасности.

Ключевые слова: ибрутиниб, ингибиторы BTK, венетоклакс, ингибиторы BCL-2, таргетные препараты, хронический лимфолейкоз.

Получено: 17 октября 2022 г.

Принято в печать: 10 ноября 2022 г.

Читать статью в PDF

Статистика Plumx русский

ЛИТЕРАТУРА

  1. Brown JR, Hallek MJ, Pagel JM. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination? Am Soc Clin Oncol Educ Book. 2016;35:e387–е398. doi: 10.1200/EDBK_159018.
  2. Eichhorst B, Fink AM, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17(7):928–42. doi: 10.1016/S1470-2045(16)30051-1.
  3. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10. doi: 10.1056/NEJMoa1313984.
  4. Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. 2018;391(10129):1524–37. doi: 10.1016/S0140-6736(18)30422-7.
  5. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. doi: 10.1056/NEJMoa1215637.
  6. de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. 2012;119(11):2590–4. doi: 10.1182/blood-2011-11-390989.
  7. Herman SE, Mustafa RZ, Jones J, et al. Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo. Clin Cancer Res. 2015;21(20):4642–51. doi: 10.1158/1078-0432.CCR-15-0781.
  8. Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440–50. doi: 10.1182/bloodadvances.2021006434.
  9. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019;381(5):432–43. doi: 10.1056/NEJMoa1817073.
  10. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med. 2018;379(26):2517–28. doi: 10.1056/NEJMoa1812836.
  11. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. doi: 10.1016/S1470-2045(18)30788-5.
  12. Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353–63. doi: 10.1002/ajh.25638.
  13. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23. doi: 10.1056/NEJMoa1400376.
  14. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373(25):2425–37. doi: 10.1056/NEJMoa1509388.
  15. Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–506. doi: 10.1182/blood-2014-10-606038.
  16. Davids MS, Brander DM, Kim HT, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019;6(8):e419–e428. doi: 10.1016/S2352-3026(19)30104-8.
  17. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8. doi: 10.1038/nm.3048.
  18. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med. 2019;380(23):2225–36. doi: 10.1056/NEJMoa1815281.
  19. Kater AP, Wu JQ, Kipps T, et al. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study. J Clin Oncol. 2020;38(34):4042–54. doi: 10.1200/JCO.20.00948.
  20. Al-Sawaf O, Zhang C, Lu T, et al. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J Clin Oncol. 2021;39(36):4049–60. doi: 10.1200/JCO.21.01181.
  21. Kittai AS, Woyach JA. uMRD: “the” endpoint or “an” endpoint for CLL? Blood. 2022;140(8):797–8. doi: 10.1182/blood.2022016927.
  22. Chen SS, Chang BY, Chang S, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30(4):833–43. doi: 10.1038/leu.2015.316.
  23. Cervantes-Gomez F, Lamothe B, Woyach JA, et al. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015;21(16):3705–15. doi: 10.1158/1078-0432.CCR-14-2809.
  24. Kater AP, Slinger E, Cretenet G, et al. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Blood Adv. 2021;5(23):5410–4. doi: 10.1182/bloodadvances.2021004861.
  25. Slinger E, Thijssen R, Kater AP, Eldering E. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia. 2017;31(12):2601–7. doi: 10.1038/leu.2017.129.
  26. Haselager MV, Kater AP, Eldering E. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing? Front Oncol. 2020;10:592205. doi: 10.3389/fonc.2020.592205.
  27. Ondrisova L, Mraz M. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. Front Oncol. 2020;10:591577. doi: 10.3389/fonc.2020.591577.
  28. Haselager MV, Kielbassa K, Ter Burg J, et al. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020;136(25):2918–26. doi: 10.1182/blood.2019004326.
  29. Deng J, Isik E, Fernandes SM, et al. Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia. 2017;31(10):2075–84. doi: 10.1038/leu.2017.32.
  30. Gutierrez C, Wu CJ. Clonal dynamics in chronic lymphocytic leukemia. Blood Adv. 2019;3(22):3759–69. doi: 10.1182/bloodadvances.2019000367.
  31. Lu P, Wang S, Franzen CA, et al. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021;11(2):39. doi: 10.1038/s41408-021-00429-z.
  32. Zhang J, Lu X, Li J, Miao Y. Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. Biomark Res. 2022;10(1):17. doi: 10.1186/s40364-022-00357-5.
  33. Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol. 2021;39(34):3853–65. doi: 10.1200/JCO.21.00807.
  34. Wierda WG, Tam CS, Allan JN, et al. Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood. 2020;136(Suppl 1):16–7. doi: 10.1182/blood-2020-134446.
  35. Ghia P, Allan JN, Siddiqi T, et al. First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study. Blood. 2021;138(Suppl 1):68. doi: 10.1182/blood-2021-144544.
  36. Tam CS, Allan JN, Siddiqi T, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139(22):3278–89. doi: 10.1182/blood.2021014488.
  37. Allan JN, Wierda WG, Siddiqi T, et al. Primary analysis of the fixed-duration cohort from the phase 2 CAPTIVATE study of first-line ibrutinib+venetoclax for chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA Library. 2021;324555:S147.
  38. Jain N, Keating M, Thompson P, et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019;380(22):2095–103. doi: 10.1056/NEJMoa1900574.
  39. Jain N, Keating MJ, Thompson PA, et al. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results. Blood. 2021;138(Suppl 1):3720. doi: 10.1182/blood-2021-154454.
  40. Jain N, Keating M, Thompson P, et al. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021;7(8):1213–9. doi: 10.1001/jamaoncol.2021.1649.
  41. Kater A, Owen C, Moreno C, et al. Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (CLB+O) for first-line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study. EHA Library. 2021;330172:LB1902.
  42. Munir T, Moreno C, Owen C, et al. First prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients: the Glow study. Blood. 2021;138(Suppl 1):70. doi: 10.1182/blood-2021-148666.
  43. Kater AP, Owen C, Moreno C, et al. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities. NEJM Evid. 2022;1(7). doi: 10.1056/EVIDoa2200006.
  44. Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. J Clin Oncol. 2019;37(30):2722–9. doi: 10.1200/JCO.19.00894.
  45. Niemann CU, Levin M-D, Dubois J, et al. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia. Blood. 2021;137(8):1117–20. doi: 1182/blood.2020008608.
  46. Jain N, Keating MJ, Thompson PA, et al. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood. 2019;134(Suppl_1):359. doi: 10.1182/blood-2019-131732.
  47. Scarfo L, Heltai S, Albi E, et al. Minimal residual disease-driven treatment intensification by sequential addition of ibrutinib to venetoclax in relapsed/refractory chronic lymphocytic leukemia: results of the monotherapy and combination phases of the IMPROVE study. Blood. 2020;136(Suppl 1):21–2.
  48. Thompson PA, Wang Y, Keating MJ, et al. Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease. Blood. 2021;138(Suppl 1):3723. doi: 1182/blood-2021-149919.
  49. Petrenko A, Kislova M, Dmitrieva E, et al. P654: Ibrutinib Plus Venetoclax in Patients With Complex Karyotype and Chronic Lymphocytic Leukemia. HemaSphere. 2022;6:552–3. doi: 10.1097/01.HS9.0000845500.06883.11.